Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JSKN016 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JSKN016 + pembrolizumab is a combination investigational anticancer regimen consisting of JSKN016, a bispecific antibody-drug conjugate (ADC) targeting both HER3 (human epidermal growth factor receptor 3) and TROP2 (trophoblast cell surface antigen 2), and pembrolizumab, a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor. JSKN016 binds HER3 and/or TROP2 on tumor cells, is internalized via endocytosis, and releases a cytotoxic topoisomerase I inhibitor payload, inducing apoptosis and also exerting a bystander effect on antigen-negative cells[1][2][3][4][6][8]. Pembrolizumab blocks interaction of PD-1 with its ligands, restoring immune response against tumor cells[9]. The combination is currently being studied for synergistic immunotherapeutic and cytotoxic activity primarily in advanced HER2-negative breast cancer and non-small cell lung cancer (NSCLC)[3][4][6].
- Other names
- JSKN016JSKN-016JSKN 016Keytrudapembrolizumab
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on JSKN016 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JSKN016 + pembrolizumab.